54gene

Over 80% of genomic data used in drug development comes from people of European descent, despite Africa having the most genetic diversity on Earth. This means drugs are developed and tested primarily for non-African populations, leading to less effective treatments for Africans and missed opportunities for precision medicine.

54gene collected African genomic data through partnerships with hospitals across Nigeria. They built a biobank of African genetic samples and offered pharmaceutical companies access to this data for drug discovery and clinical trials. The goal was to ensure Africans were represented in the development of new medicines.

Raised $45M in Series B, reaching a reported $500M valuation. Collected over 100,000 genetic samples from Nigerian hospitals. Signed partnerships with major pharmaceutical companies. However, burned through capital rapidly, and by late 2023, had laid off most staff and paused operations.

A brilliant mission and real market need don't guarantee a viable business model. The gap between collecting data and generating revenue was years longer than the burn rate could sustain. African deep-tech companies need patient capital structures, not Silicon Valley-style funding timelines.